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Introduction
Non-adherence to treatment for tuberculosis is a major barrier 
to global tuberculosis control. To ensure adherence to treatment 
by tuberculosis patients, the direct observation of treatment by 
a trained supervisor is recommended.1 Initially, such directly 
observed treatment (DOT) was provided in health-care facilities 
only, but because of workload demands, several countries have 
started to involve community members in the provision of DOT.2 
Studies have shown that community-based DOT is a cost-effective 
strategy that yields treatment outcomes similar to those obtained 
with facility-based DOT.3–6 However, community-based DOT 
has been criticized for being beyond the control of health-care 
providers and hence conducive to self-administered (unsupervised) 
treatment and non-adherence.6,7
The actual degree of adherence by patients on community-
based DOT has not yet been assessed. Measuring adherence is 
difficult because most available direct and indirect measures have 
limitations. Direct adherence measures, such as tests to measure 
drug levels in plasma or urine, cover brief medication intake pe-
riods only. Indirect measures, such as pill counts and self-report 
questionnaires, cover longer periods but assume rather than prove 
the patient’s actual medication intake.8
A sophisticated indirect adherence measure is the Medication 
Event Monitoring System (MEMS). MEMS medication bottles 
contain a microelectronic chip that registers the date and time of 
every bottle opening. Assuming that bottle openings represent 
medication intake, MEMS provides a detailed profile of the pa-
tient’s adherence behaviour. MEMS is currently regarded as the 
gold standard to measure adherence.8 It has been used as such in a 
wide range of studies on adherence to antihypertensive and lipid-
lowering therapy,9,10 therapy for neurologic and psychiatric disor-
ders,11,12 post-transplantation immunosuppressive therapy13,14 and 
antiretroviral therapy.15–17 Few studies report on the use of MEMS 
to monitor adherence to tuberculosis treatment.18–21 Because of the 
high cost involved, MEMS is not feasible for use in routine practice 
in most settings with a high tuberculosis burden but could be used 
as a reference standard to validate simple and affordable measures 
that can be used in patients on community-based DOT.8,21
In this pilot study, we used MEMS to: (i) describe adherence 
rates among Tanzanian tuberculosis patients on community-based 
DOT and (ii) determine the validity of several direct and indirect 
adherence measures of potential use in resource-limited settings.
Methods
Study setting
The study was conducted in the Kilimanjaro region of the United 
Republic of Tanzania, where the annual tuberculosis case notifica-
tion rate is 178 per 100 000 population.6 The national tuberculosis 
programme empowers patients to choose between community- and 
facility-based DOT. Most patients opt for community-based DOT 
and those on facility-based DOT are mostly inpatients.6 Patients 
on community-based DOT have to select a treatment supporter 
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from their community (usually a relative 
or spouse) who is instructed on how to 
provide daily DOT at home. Patients on 
community-based DOT are supposed 
to collect their medication once a week 
in the first two months of treatment and 
once every two weeks in the remaining 
four months. They should return medica-
tion blisters for pill counts and their clinic 
attendance is registered.22
Study design and procedures
This was a longitudinal pilot study in which 
treatment adherence among 50 patients on 
community-based DOT was monitored by 
MEMS throughout treatment. MEMS was 
used as a gold standard to validate several 
other adherence measures (single and in 
combinations) in this patient group. The 
adherence measures were selected for their 
applicability in the Tanzanian setting and 
included an isoniazid (INH) urine test, a 
urine colour test for rifampicin, the Brief 
Medication Questionnaire (BMQ), the 
Morisky scale, an adapted version of the 
AIDS Clinical Trials Group (ACTG) 
adherence questionnaire, pill counts and 
clinic attendance for medication refills.
The participants were recruited be-
tween February and May 2010 from one 
rural hospital, one urban hospital and two 
urban health centres. Considering the pi-
lot nature of our study, we chose to enrol 
50 patients only. Adult outpatients who 
consecutively presented at one of the study 
sites with newly diagnosed tuberculosis and 
who had chosen community-based DOT 
were eligible to participate. Eligible patients 
were informed about the study procedures 
by trained clinic staff and asked to sign an 
informed consent form. They were told 
that their tuberculosis medication would 
be provided in a medication bottle with 
a microelectronic chip that registers every 
bottle opening. They were asked not to use 
the MEMS bottle for other medication, to 
open it only to take out medication, and to 
bring the bottle to every medication refill 
visit. Patients were informed that they 
would be under routine treatment and care.
Drug dispensing nurses were responsi-
ble for providing patients with medication. 
Medication refill visits were conducted in 
accordance with routine practice, except 
that the medication blisters were cut into 
pieces to make them fit in the MEMS 
bottle. The nurses registered the dates of 
the patients’ clinic visits for medication 
refills and the number of tablets remaining 
at each visit. During the visits in weeks 4, 
8, 12 and 16, the procedures deviated from 
routine practice. At these visits, patients 
submitted a sample of urine and were 
asked to fill out the BMQ and Morisky 
scale (in weeks 4, 8 and 12) or the ACTG 
adherence questionnaire (in week 16). At 
completion of treatment, the patients filled 
out a questionnaire about their experience 
with the use of MEMS bottles.
Treatment adherence measures
Medication Event Monitoring System
MEMS medication bottles (250-ml con-
tainers with a 38-mm MEMS 6 TrackCap, 
AARDEX Ltd, Sion, Switzerland) were 
used by all participants throughout treat-
ment. MEMS data were used to calculate 
adherence rates (by dividing the number 
of days on which at least one bottle open-
ing was registered by the total number of 
monitored days and multiplied by 100) 
and to differentiate between adherent 
and non-adherent patients for validation 
of the other adherence measures. For the 
latter purpose, commonly used adherence 
rate cut-off values of 100%, 95% and 80% 
were applied.8
Isoniazid urine test
The isoniazid urine test or IsoScreen test 
(GFC Diagnostics Ltd, Bicester, England) 
is based on the Arkansas method for the 
detection of INH in urine and supplied in 
a ready-to-use plastic testing device. The 
test was performed in accordance with 
the directions provided in the accompa-
nying manual. The test result was negative 
when no colour change was observed 
after 5 minutes, positive when the colour 
changed to dark purple and equivocal when 
the colour turned green. Patients with at 
least one negative test were regarded as 
non-adherent.
Urine colour test
Prior to each INH urine test, urine colour 
was checked for the presence of rifampicin. 
Orange urine was scored as positive and 
yellow urine as negative. Patients with at 
least one negative test were categorized as 
non-adherent.
Morisky scale
The Morisky scale is a self-report adherence 
measure with four questions about com-
mon barriers to adherence.23 We classified 
as non-adherent all patients who answered 
“yes” to at least one of the four questions 
in at least one of the three repeated tests.
Brief Medication Questionnaire
The BMQ consists of three sections 
(“screens”) with questions about adher-
ence behaviour, the experienced effects 
of treatment and other factors that could 
affect adherence. The screens were scored 
as described elsewhere.24 Patients with a 
total score of 1 or more in at least one of 
the three repeated tests were classified as 
non-adherent.
AIDS Clinical Trials Group adherence 
questionnaire
The adapted ACTG adherence question-
naire was developed for patients infected 
with the human immunodeficiency virus 
(HIV) who participate in clinical trials25 
and is available at www.ghdonline.org/
uploads/ACTG_Adherence_Baseline_
Questionnaire.pdf (last accessed: 12 May 
2011). Our adapted version consisted of 
three multiple choice items corresponding 
to sections B (social support), C (possible 
reasons for non-adherence) and D (adher-
ence behaviour) of the original baseline 
questionnaire. We scored any answer other 
than “never” to the questions in sections 
C and D or less than “somewhat satisfied” 
to the questions in section B as positive. A 
positive score was regarded as indicative of 
non-adherence.
Refill visits and pill counts
The patients’ clinic attendance for medica-
tion refills was registered and remaining 
tablets were counted at every refill visit. 
Patients who delayed at least once for a 
medication refill visit and those who had 
an incorrect number of tablets remaining at 
least once were classified as non-adherent.
Data analysis
MEMS data were analysed by using Pow-
erview software (AARDEX Ltd, Sion, 
Switzerland). Periods of “pocket dosing” 
(i.e. taking out medication for later use) 
that were identified by the MEMS use 
questionnaire were excluded from the 
analysis as non-monitored periods. Statisti-
cal analysis was performed in SPSS version 
16.0 (SPSS Inc., Chicago, United States 
of America). Means are presented with 
standard deviation (SD) and medians with 
interquartile range (IQR). Means were 
compared by using the Student t-test. The 
sensitivity, specificity, positive and negative 
predictive values and accuracy of single and 
combined adherence measures were calcu-
lated by using MEMS as the gold standard. 
For combined measures, non-adherent 
patients were those who were classified as 
non-adherent by at least one of the single 
measures in the combination.
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Ethical approval
The study was approved by the insti-
tutional review board of the Kiliman-
jaro Christian Medical Centre (Moshi, 
United Republic of Tanzania) and the 
National Institute for Medical Re-
search (Dar es Salaam, United Republic 
of Tanzania).
Results
Patient characteristics and 
treatment outcomes
We enrolled 31 male and 19 female pa-
tients. Their characteristics are summarized 
in Table 1. Six of the 22 patients who were 
co-infected with HIV used antiretroviral 
medication and 14 were on co-trimoxazole 
prophylaxis. Although all patients were 
on community-based DOT, seven had no 
formal treatment supporter.
Thirty-seven patients successfully 
completed treatment. Six patients died; 
all were HIV-positive. Three patients de-
faulted and four patients dropped out of 
the study (three were transferred to another 
region and one developed jaundice and his 
treatment had to be interrupted).
Treatment adherence according to 
MEMS
No MEMS data were available for three 
patients (one defaulter and two who died) 
because the medication bottle was not 
returned. For the other 47 patients, a total 
of 6871 treatment days were monitored 
by MEMS. On 194 monitored days the 
MEMS bottle was not opened; the median 
per patient was 2 days (IQR: 0–5). The 
mean adherence rate was 96.3% (SD: 7.7) 
and did not differ significantly between 
patients with and without a treatment sup-
porter: 96.2% (SD: 8.2) and 97.1% (SD: 
3.1), respectively (P = 0.79).
Adherences was less than 100% in 
70% of all patients; less than 95% in 21% 
of them, and less than 80% in 2% (Table 2). 
Among the patients who completed the six-
month treatment course, adherence was less 
than 100% in 73%, less than 95% in 19% 
and less than 80% in none, respectively.
Monthly adherence rates were fairly 
constant. In the group of patients who 
completed treatment, the median monthly 
adherence rate was 100% and the mean 
monthly adherence rate varied between 
95.4% (SD: 7.3) in month 6 and 98.5% 
(SD: 2.7) in month 3.
Validation of adherence measures
For the validation of the alternative adher-
ence measures only patients who com-
pleted the six-month treatment course 
(n = 37) were included. As shown in Fig. 1, 
the proportions of non-adherent patients 
identified by the different measures varied 
widely. Table 3 shows the sensitivity, speci-
ficity, positive and negative predictive value 
and accuracy of the adherence measures 
in terms of their ability to differentiate 
between adherent and non-adherent 
patients. The ACTG adherence question-
naire and urine colour test had the highest 
sensitivities but lowest specificities. The 
Morisky scale and refill visits had the high-
est specificities but lowest sensitivities. The 
sensitivities of most measures improved 
when the cut-off value to differentiate be-
Table 1. Patient characteristics and treatment outcomes among participants (n = 50) 


















Smear positive PTB 16 (32)



















   Cured 12 (24)
   Treatment completed 25b (50)
Unfavourable
   Died 6 (12)
   Defaulted 3 (6)
   Study drop-out 4 (8)
EPTB, extrapulmonary tuberculosis; HIV, human immunodeficiency virus; PTB, pulmonary tuberculosis; SD, 
standard deviation; TB, tuberculosis.
a All except for age, which is expressed as the mean and standard deviation.
b All had smear-negative PTB or EPTB.
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tween adherent and non-adherent patients 
was lowered from 100% to 95% adherence, 
but the specificities dropped. The positive 
and negative predictive values were almost 
reversed by changing the cut-off value from 
100% to 95%, reflecting the large difference 
in the proportions of patients categorized 
as non-adherent by using the former versus 
the latter cut-off value. A cut-off value of 
80% could not be applied because none of 
the patients who completed treatment was 
less than 80% adherent.
The combination of pill counts and 
refill visits that is used in routine practice 
had moderate sensitivity and specificity. Its 
sensitivity and negative predictive value for 
the identification of patients who were less 
than 95% adherent improved by adding 
any of the other adherence measures except 
the Morisky scale (Table 3).
Patients’ experience with MEMS 
use
The questionnaire about the use of MEMS, 
which was filled out by the 37 patients who 
completed treatment, revealed that only 
one patient had correctly understood the 
purpose of MEMS despite verbal and writ-
ten information at the onset of the study. 
Twenty-five patients (68%) stated that the 
white, bulky appearance of the MEMS 
bottle reminded them to take the medica-
tion. However, the other patients said that 
the use of MEMS had not influenced their 
adherence behaviour. Mean adherence rates 
did not differ between these two groups: 
97.5% (SD: 3.0) and 97.3% (SD: 3.2), 
respectively (P = 0.86).
Eight patients occasionally opened 
the MEMS bottle to take out medication 
for later use (resulting in a total of 42 non-
monitored treatment days). This usually 
occurred when patients did not want to 
take the bottle along on travel occasions.
Discussion
This is the first study in which MEMS was 
used to assess treatment adherence rates in 
patients on community-based DOT over 
the full six-month tuberculosis treatment 
course. We observed high adherence rates 
in our pilot study of 50 Tanzanian patients. 
Almost 80% of the patients were more 
than 95% adherent and only one patient 
was less than 80% adherent. These findings 
do not confirm the concern that patients 
on community-based DOT are prone to 
become non-adherent, even though the 
study did reveal that some patients (i.e. 
those without a formal treatment sup-
porter) turn community-based DOT into 
unsupervised treatment.
The participants’ demographic char-
acteristics, such as the ratio of males to 
females and their treatment outcomes, 
were comparable to those of the gen-
eral tuberculosis patient population in the 
Kilimanjaro region.6 This suggests that we 
studied a regionally representative patient 
sample. However, the adherence rates of 
our patients could have been biased by 
their participation in the study. Although 
we tried to deviate as little as possible from 
routine practice, the repeated adherence 
questionnaires and urine tests certainly 
made participants aware of our interest 
in their adherence behaviour. Two thirds 
of the patients felt that their adherence 
behaviour had been influenced by the use 
of MEMS, but their average adherence rate 
did not differ from those observed among 
patients who stated that MEMS had not 
influenced their behaviour. Findings from 
other studies suggest that when MEMS is 
used over long periods, its “interventional 
Table 2. Median monitored treatment days and adherence rates, and proportions of patients who were less than 100%, 95% and 
80% adherent,a as assessed by the Medication Event Monitoring System (MEMS), United Republic of Tanzania, 2010








Median (IQR)b Median (IQR)b No. (%) No. (%) No. (%)
All (47) 168 (138–172) 98.4 (95.7–100) 33 (70) 10 (21) 1 (2)
Completed treatment (37) 169 (168–180.5) 98.4 (95.7–100) 27 (73) 7 (19) 0 (0)
Defaulters (2) 40.0/113c 50.0/100d 1 (50) 1 (50) 1 (50)
Deaths (4) 63 (29.5–104) 98.4 (95.6–99.6) 3 (75) 1 (25) 0 (0)
Study drop outs (4) 33 (21–73) 98.3 (88.4–100) 2 (50) 1 (25) 0 (0)
IQR, interquartile range.
a Only patients for whom MEMS data were available are included.
b All values given are medians and IQRs except for the values of the two defaulters.
c Number of monitored days for defaulter 1 and defaulter 2, respectively.
d Adherence rates of defaulter 1 and defaulter 2, respectively.
Fig. 1. Non-adherence to tuberculosis treatment among patients who completed 
treatment (n = 37) as assessed by different adherence measures, United 
Republic of Tanzania, 2010
0
Refill visits









10 20 30 40 50 60 70 80 90 100
ACTG, AIDS Clinical Trials Group; BMQ, Brief Medication Questionnaire; INH, isoniazid; MEMS, Medication Event 
Monitoring System.
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effect” disappears.26,27 Since our sample size 
was small, larger population studies should 
be conducted to assess the real impact of 
community-based DOT with and without 
formal treatment supporter on adherence 
rates. We did not aim to validate the con-
cept of community-based DOT; studies for 
this purpose should have a different design.
The main objective of our study was 
to use MEMS as a reference standard to 
calculate the validity of several adherence 
measures whose use is feasible in patients 
on community-based DOT in resource-
limited settings. The high adherence rates 
in the study population forced us to ap-
ply high adherence rate cut-off values to 
calculate the validity and reliability of the 
adherence measures. This resulted in wide 
gaps between the sensitivities and speci-
ficities of the measures.8 Combinations of 
measures were found to be more accurate 
than single measures in identifying as many 
true non-adherent patients as possible 
(reflected in high sensitivities and nega-
tive predictive values). The sensitivity and 
negative predictive value of the routinely 
used combination of pill counts and clinic 
attendance for medication refills improved 
substantially by adding a simple and cheap 
measure such as the ACTG adherence 
questionnaire, particularly at an adherence 
rate cut-off value of 95%.
The rifampicin urine colour test clas-
sified more patients as non-adherent than 
the INH urine test. Since the orange urine 
colouration caused by rifampicin is of short 
duration and may be absent altogether,28 it 
is likely that the urine colour test misclas-
sified some patients with yellow urine as 
non-adherent. Such misclassifications are 
difficult to confirm in a study population 
with high adherence rates.
The adapted ACTG adherence ques-
tionnaire yielded more favourable re-
sponses than the other self-report measures. 
Differences in wording in the question-
naires may account for this.8 While patients 
had to answer either “yes” or “no” to the 
questions in the Morisky scale, they could 
answer “often”, “sometimes”, “rarely”, or 
“never” to comparable questions in the 
ACTG adherence questionnaire. This wid-
er range of choice options may have evoked 
more honest replies. The ACTG adherence 
questionnaire (and to a lesser extent the 
BMQ) has the added advantage of disclos-
ing factors that cause non-adherence in the 
individual patient. These factors could be 
used to design tailored interventions for 
promoting adherence among non-adherent 
patients on community-based DOT. We 
therefore suggest using the triple combina-
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questionnaire, refill visits and pill counts 
to monitor treatment adherence by Tanza-
nian patients on community-based DOT. 
If the results are interpreted carefully, the 
combination seems valid and its use in 
routine practice appears feasible.
In conclusion, this study revealed high 
levels of treatment adherence by Tanza-
nian tuberculosis patients on community-
based DOT. Although caution should 
be exercised in interpreting the results 
because this is a pilot study, the findings 
support the recommendation of using 
community-based DOT as an alterna-
tive to facility-based DOT in settings 
with overburdened health-care facilities. 
To monitor adherence among patients 
on community-based DOT in resource-
limited settings where electronic monitor-
ing is not feasible, combinations of simple 
and affordable adherence measures can be 
used. Supplementing pill counts and clinic 
attendance with a self-report measure such 
as the ACTG adherence questionnaire will 
help to identify potentially non-adherent 
patients who could benefit from tailored 
adherence-promoting interventions. Fur-
ther studies in larger patient populations 
are needed to assess the adherence rates of 
patients on community-based DOT and to 
confirm the validity of simple and afford-
able adherence measures. ■
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Résumé
Suivi électronique de l’adhésion au traitement et validation de mesures d’adhésion alternatives des patients 
tuberculeux: une étude pilote
صخلم
ةيدايترا ةسارد :لسلا ضىرم ينب جلاعلل لاثتملال ةليدبلا يربادتلا ةيقودصم قيثوتو جلاعلل لاثتملال ةينوتركللإا ةبقارلما
 شرابلما  فاشرلإا  تحت  زكترلما  ةيعمتجلما  ةجلاعملل  لاثتملاا  سايق  ضرغلا
 قيثوتو  ،ةاوادلما  ثدح  ةبقارم  ماظن  مادختساب  اينازنت  في  لسلا  ضىرم  ينب
 دراولما  ةدودحلما  عقاولما  في  جلاعلل  لاثتملال  ةليدبلا  يربادتلا  ةيقودصم
.لياثم رايعمك ةاوادلما ثدح ةبقارم ماظن مادختساب
 مت  ًاضيرم  50  لىع  ةيدايترلاا  ةينلاوطلا  ةساردلا  هذه  تيرجأ  ةقيرطلا
 ،ةيضرحلا تايفشتسلما دحأو ،ةيفيرلا تايفشتسلما دحأ نم لياوتلاب مهجاردإ
 ماظن قيرط نع جلاعلل مهلاثتما ةبقارم ىرجو .ينيضرح ينيحص نيزكرم نمو
 :جلاعلل مهلاثتملا ةيلاتلا  يربادتلا  ةيقودصم سيق ماك ةاوادلما ثدح ةبقارم
 ،Morisky  كيسيروم  زرحو  ،لوبلا  نول  رابتخاو  ،ليوبلا  ديزاينوزيلأا  رابتخا
 ةيريسرلا  براجتلا  ةعومجم  نم هفييكت  ىرج ةاوادلما  نع زجوم نايبتساو
 تارايزو  ،ءاودلا  بوبح  دادعتو  ،جلاعلل  لاثتملاا  نع  نايبتساو  ،زديلإا  نع
.ءاودلاب دادملإا ةداعإ
 96.3%  ةساردلا  في  ينَجردُلما  ينب  جلاعلل  لاثتملاا  لدعم  ناك  جئاتنلا
 70% في 100% نم لقأ  جلاعلل  لاثتملاا  ناكو  .)7.7  :يرايعلما  فارحنلااو(
 ناكو  .2% في  80% نم  لقأو  ،مهنم  21% في 95% نم  لقأو  ،ضىرلما  نم
 رابتخاو  زديلإا  نع  ةف َّيكُلما  ةيريسرلا  براجتلا  ةعومجبم  صاخلا  نايبتسلاا
 زرح ناكو .ةيعونلا في لقلأا نكلو ةيساسحلا ثيح نم لىعلأا ماه لوبلا نول
 نكلو ةيعونلا ثيح نم لىعلأا ماه ءاودلاب دادملإا ةداعإ تارايزو كيسيروم
 ةداعإ  تارايز  عم  ءاودلا  بوبح ددع  جمد  ىدأ  دقو  .ةيسايسحلا  في  لقلأا
 ةيعونو ةيساسح لىإ ،ةينيتورلا ةسرمالما في مدختسم وه ماك ،ءاودلاب دادملإا
 صاخلا  لاثتملاا  نايبتسا  ةفاضإ  دنع  ةيساسحلا  تنسحت  دقو  ،ينتطسوتم
.زديلإا نع ةيريسرلا براجتلا ةعومجبم
 شرابلما فاشرلإا تحت دملأا يرصقلا جلاعلل نوعضاخلا ضىرلما رهظأ جاتنتسلاا
 جيزم مادختسا نكيمو .جلاعلل ًاديج ًلااثتما ةساردلا هذه في زكترلما يعمتجلما
 لاثتملاا  نايبتساو  ،ءاودلاب  دادملإا  ةداعإ  تارايزو  ،جلاعلا  بوبح ددع  نم
 في  جلاعلل  لاثتملاا  ةبقارلم  زديلإا  نع  ةيريسرلا  براجتلا  ةعومجبم  صاخلا
 دكأتلا بجيو .ةاوادلما ثدح ةبقارم ماظن دوجو اهيف سريتي لا يتلا عقاولما
 لىع ةطيسبلا لاثتملاا يربادت ةيقادصم قيثوتو لاثتملااب ةصاخلا جئاتنلا نم


























Objectif Évaluer l’adhésion au traitement directement observé en milieu 
communautaire des patients tuberculeux tanzaniens, à l’aide du système de 
suivi des événements de médication (MEMS, Medication Event Monitoring 
System) et valider les mesures d’adhésion alternatives dans les configurations 
de ressources limitées utilisant le MEMS comme critère de référence.
Méthodes Il s’agissait d’une étude pilote longitudinale sur 50 patients 
recrutés consécutivement dans un hôpital rural, un hôpital urbain et deux 
centres de soins urbains. L’adhésion au traitement a été contrôlée par le 
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Резюме
Электронный мониторинг приверженности к лечению и проверка действенности альтернативных 
мер по контролю приверженности у больных туберкулезом (пилотное исследование)
Цель Оценить приверженность к лечению, проводившемуся 
на базе общины под непосредственным наблюдением 
врача, у туберкулезных больных в Танзании с применением 
Системы электронного мониторирования выдачи 
препарата (Medication Event Monitoring System, MEMS) и 
проверить действенность альтернативных мер по контролю 
приверженности в условиях ограниченности ресурсов, 
используя MEMS в качестве «золотого стандарта».
Методы Проведено лонгитюдное пилотное исследование 
50 пациентов, отобранных последовательно из сельской 
больницы, городской больницы и двух городских 
медицинских центров. Мониторинг приверженности к 
лечению осуществлялся с помощью MEMS; проводилась 
также проверка действенности следующих мер по контролю 
приверженности: анализа мочи при приеме изониазида, 
контроля цвета мочи, применения шкалы Morisky, 
Краткого опросника по лекарственным препаратам (Brief 
Medication Questionnaire, BMQ) и адаптированного варианта 
«Опросника по приверженности» Группы клинических 
испытаний по СПИДу (ACTG), а также подсчета таблеток 
и посещения больных с целью пополнения запаса лекарств.
Результаты Средний показатель приверженности в 
исследуемой популяции составлял 96,3% (стандартное 
отклонение, СО: 7,7). У 70% больных показатель 
приверженности был ниже 100%, у 21% – ниже 95% и у 2% 
ниже 80%. При применении опросника ACTG и контроля 
цвета мочи достигалась максимальная чувствительность 
при минимальной специфичности. Применение шкалы 
Morisky и визитов для пополнения запаса лекарств 
давало максимальную специфичность при минимальной 
чувствительности. Использование в рутинной практике 
подсчета таблеток в сочетании с посещениями больных 
для пополнения запаса лекарств обеспечивали умеренную 
чувствительность и специфичность, однако при добавлении 
опросника ACTG чувствительность повышалась.
Вывод В данном исследовании пациенты, проходившие 
лечение под непосредственным наблюдением врача (DOT) 
на уровне общины, продемонстрировали высокий уровень 
приверженности. Для отслеживания приверженности 
больных к лечению в условиях, когда применение MEMS 
недоступно по финансовым причинам, можно применять 
подсчет таблеток, посещение больных с целью пополнения 
запаса лекарств и «Опросник по приверженности» ACTG. 
Полученные результаты, касающиеся приверженности 
к лечению и действенности простых мер контроля 
приверженности больных к лечению, необходимо 
подтвердить на примере более крупных популяций при 
широком разбросе значений показателя приверженности.
Resumen
Control electrónico del cumplimiento terapéutico de pacientes con tuberculosis y validación de medidas 
alternativas de cumplimiento: estudio piloto
Objetivo Evaluar el cumplimiento de los tratamientos observados 
directamente que están dirigidos a la comunidad por parte de los pacientes 
con tuberculosis en Tanzania, mediante el Sistema de vigilancia de la 
medicación (Medication Event Monitoring System [MEMS]) y validar medidas 
alternativas de cumplimiento para los entornos de recursos limitados, 
empleando los MEMS como método de referencia.
Métodos Se realizó un estudio piloto longitudinal con 50 pacientes 
seleccionados consecutivamente de un hospital rural, un hospital urbano y 
dos centros sanitarios urbanos. El cumplimiento terapéutico se controló con 
el MEMS y se evaluó la validez de las siguientes medidas de cumplimiento: 
detección de isoniacida en orina, prueba de color de la orina, test de Morisky, 
Cuestionario breve de medicación, cuestionario adaptado del cumplimiento 
terapéutico del Grupo de Ensayos Clínicos sobre el SIDA (ACTG), recuento 
de la medicación y visitas de aprovisionamiento de medicamentos.
Resultados La tasa media de cumplimiento en la población del estudio fue 
de un 96,3% (desviación estándar, DE: 7,7). El cumplimiento fue inferior 
al 100% en el 70% de los pacientes, inferior al 95% en el 21% de los 
pacientes e inferior al 80% en el 2% de los pacientes. El cuestionario 
de cumplimiento ACTG y la prueba de color de la orina registraron los 
niveles más elevados de sensibilidad y los más bajos de especificidad. 
El test Morisky y las visitas de aprovisionamiento de medicamentos 
obtuvieron los niveles más elevados de especificidad y los más bajos de 
sensibilidad. La combinación del recuento de medicamentos y las visitas 
de aprovisionamiento, empleada en la práctica habitual, registró una 
sensibilidad y una especificidad moderadas, si bien la sensibilidad aumentó 
cuando se añadió el cuestionario de cumplimiento ACTG.
Conclusión Los pacientes que siguieron un tratamiento observado 
directamente y dirigido a la comunidad mostraron un cumplimiento correcto 
MEMS et la validité des mesures d’adhésion conséquentes a été évaluée: 
test urinaire pour détecter la présence d’isoniazide, test de coloration 
des urines, échelle de Morisky, bref questionnaire sur la médication, 
questionnaire d’adhésion adapté du Groupe d’essais cliniques du SIDA 
(ACTG, AIDS Clinical Trials Group), décomptes de pilules et visites de 
réapprovisionnement en médicaments.
Résultats Le taux d’adhésion moyen dans la population de l’étude 
atteignait 96,3% (déviation standard, DS: 7,7). L’adhésion était inférieure 
à 100% chez 70% des patients, inférieure à 95% chez 21% d’entre eux 
et inférieure à 80% chez 2% d’entre eux. Le questionnaire d’adhésion de 
l’ACTG et le test de coloration des urines présentaient les sensibilités les 
plus élevées, mais les spécificités les plus basses. L’échelle de Morisky et 
les visites de réapprovisionnement présentaient les spécificités les plus 
élevées, mais les sensibilités les plus basses. Les décomptes de pilules 
et les visites de réapprovisionnement en médicaments combinés, utilisés 
dans la pratique de routine, montraient une sensibilité et une spécificité 
modérées, mais la sensibilité s’améliorait lors de l’ajout du questionnaire 
d’adhésion de l’ACTG.
Conclusion Les patients suivant un traitement directement observé 
en milieu communautaire ont montré une meilleure adhésion dans 
cette étude. La combinaison des décomptes de pilules, des visites de 
réapprovisionnement et du questionnaire d’adhésion de l’ACTG a pu être 
utilisée pour contrôler l’adhésion dans les cadres où le MEMS n’était pas 
abordable. Les résultats en termes d’adhésion et de validité des mesures 
d’adhésion simples devraient être confirmés auprès de populations plus 
larges, avec une variabilité plus importante des taux d’adhésion. 
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en este estudio. La combinación del recuento de medicación, las visitas 
de aprovisionamiento de medicamentos y el cuestionario de cumplimiento 
ACTG podría emplearse para controlar el cumplimiento en entornos en 
los que el uso del sistema MEMS no resulte viable económicamente. Los 
resultados en cuanto al cumplimiento y a la validez de las medidas sencillas 
de cumplimiento podrían confirmarse en poblaciones más amplias con 
una mayor variabilidad de sus tasas de cumplimiento. 
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